Review
Clinical Neurology
Beatriz Corte-Real, Rodrigo Saraiva, Catarina Rodrigues Cordeiro, Benicio N. Frey, Flavio Kapczinski, Taiane de Azevedo Cardoso
Summary: The study aimed to investigate whether atypical antipsychotics (AA) can induce mania in mood disorders. A systematic review and meta-analysis showed that AA-induced mania is rare and the use of AA is more effective in preventing the development of mania compared to placebo.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Review
Medicine, General & Internal
Andreas S. Lappas, Bartosz Helfer, Katarzyna Henke-Ciazynska, Myrto T. Samara, Nikos Christodoulou
Summary: This systematic review and meta-analysis assessed the efficacy, tolerability, and acceptability of Clonazepam in the treatment of acute mania. The results suggested that Clonazepam may be superior to a placebo in the acute phase of treatment and comparable to Lithium and Haloperidol in terms of efficacy, both acutely and in the medium to long term. Clonazepam may be an acceptable and well-tolerated treatment for acute mania, especially when used as an augmentation strategy. However, the limited sample sizes and underpowered comparisons restrict the generalizability of the findings and hinder firm clinical conclusions.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Psychiatry
Roberto Palacios-Garran, Vicent Llorca-Bofi, Gara Arteaga-Henriquez, Enrique Del Agua
Summary: The study aimed to evaluate the efficacy and safety of cariprazine in combination with mood stabilizers for treating Female Emotional Dysregulation. The results showed that over half of the patients demonstrated adherence to treatment, indicating good safety and effectiveness of the treatment approach.
FRONTIERS IN PSYCHIATRY
(2022)
Review
Neurosciences
Ashish Patel, Arya Patel, Darshini Patel, Krina Patel, Tushar Bambharoliya
Summary: Cariprazine is a novel atypical antipsychotic drug that was approved by the USFDA in 2015 for the treatment of schizophrenia and bipolar manic or mixed episodes in adults. It differs pharmacologically from other antipsychotic drugs due to its partial agonist action on dopamine and serotonin receptors. It also has a unique pharmacokinetic profile due to the formation of two significant metabolites. This review study demonstrates the effectiveness and safety of cariprazine in bipolar I disorder and schizophrenia, highlighting its potential as a promising therapeutic alternative.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
(2023)
Article
Behavioral Sciences
Zackary A. Cope, Johnny A. Kenton, Arpi Minassian, Maureen V. Martin, William Perry, Christoffer Bundgaard, Jorn Arnt, Jordy van Enkhuizen, Mark A. Geyer, Jared W. Young
Summary: The study highlights the different responses of DAT knockdown mice to risperidone and asenapine in mania behavior, pointing out the limitations of current treatment methods, and further emphasizes the necessity of resources and research into DAT-targeting drugs.
BEHAVIOURAL BRAIN RESEARCH
(2021)
Review
Neurosciences
Janusz K. Rybakowski
Summary: Antipsychotic drugs have been widely used in the treatment of mood disorders in addition to schizophrenia since their first application in psychiatry seventy years ago. These drugs can be classified into three generations, and each generation has different effects on mood disorders. The second and third generations of antipsychotic drugs have shown efficacy in the treatment of bipolar disorder, including antimanic and antidepressant effects.
Article
Pediatrics
Todd Riccobene, Robert Riesenberg, Paul P. Yeung, Willie R. Earley, Arlene L. Hankinson
Summary: This study investigated the pharmacokinetics, safety, and tolerability of Cariprazine in pediatric patients with schizophrenia or bipolar I disorder. The results showed that Cariprazine had consistent pharmacokinetic parameters with adults and was safe and tolerable in children and adolescents.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
(2022)
Review
Neurosciences
Prakamya Singal, Nicolas A. Nunez, Boney Joseph, Leslie C. Hassett, Ashok Seshadri, Balwinder Singh
Summary: This systematic review evaluated the efficacy and safety of clonidine, an alpha-2 adrenergic agonist, for acute mania/hypomania. The findings suggest that clonidine may have some effectiveness as an adjuvant treatment, but the results from randomized controlled trials are inconsistent. Common adverse effects include hypotension, depression, and somnolence. Further research in well-designed randomized controlled trials is needed to determine the efficacy of clonidine as a monotherapy.
Article
Clinical Neurology
Luis R. Patino, Maxwell J. Tallman, Hongbo Wen, Caleb M. Adler, Jeffrey A. Welge, Melissa P. DelBello
Summary: The objective of this study was to evaluate differences in sustained attention and associated neurofunctional profiles between bipolar disorder type I, attention-deficit/hyperactivity disorder, and healthy comparison youth. Adolescent participants underwent MRI while completing a modified Continuous Performance Task. BD participants displayed deficits in sustained attention and lower activation in brain regions associated with performance and neural integration. These differences were distinct to the BD group and not attributable to ADHD comorbidity.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Clinical Neurology
Tong Guo, Yuan Yang, Qian Zhao, Lei Zhang, Chee H. Ng, Teris Cheung, Yang Li, Xue-Quan Zhu, Xiao-Hong Li, Yu-Tao Xiang
Summary: The study aimed to assess the clinical phenomenology and characteristics of prodromal symptoms in Chinese patients with bipolar disorder prior to their index mood episode. The findings indicated that identifying prodromal symptoms of BPD may be beneficial for early diagnosis and intervention before the development of full episodes.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Psychiatry
Jane E. Persons, Paul Lodder, William H. Coryell, John Nurnberger, Jess G. Fiedorowicz
Summary: This study found that manic and anxiety symptoms did not significantly contribute to suicidal ideation and behavior in individuals with bipolar disorder during a depressive state, with the main risk factor being severe depressive symptoms. The limitations of small sample size and measurement tools may have influenced these findings, suggesting future studies would benefit from larger samples and more rigorous assessments.
PSYCHIATRY RESEARCH
(2022)
Article
Psychiatry
F. Pacchioni, F. Casoni, A. Sarzetto, F. Attanasio, B. Barbini, M. Locatelli, C. Colombo, M. C. Cavallini, L. Fregna
Summary: Sleep plays a crucial role in the development and manifestation of mood disorders, but few studies have examined sleep architecture during manic episodes of Bipolar Disorder (BD) and changes in sleep parameters. This study investigated 21 BD patients in the manic phase and found that their sleep quantity and quality improved during hospitalization, accompanied by clinical improvement. The study also revealed an increase in REM sleep. These findings suggest that changes in sleep architecture can serve as sensitive markers for clinical variations during manic phases of Bipolar Disorder.
PSYCHIATRY RESEARCH
(2023)
Review
Clinical Neurology
Margherita Barbuti, Giulia Menculini, Norma Verdolini, Isabella Pacchiarotti, Georgios D. Kotzalidis, Alfonso Tortorella, Eduard Vieta, Giulio Perugi
Summary: The present systematic review aimed to summarize the evidence about treatment-emergent mood switches in patients with bipolar disorder (BD). Thirty-two original studies met the inclusion criteria, and the majority focused on manic switches with limited research on depressive switches. Treatment-emergent mania/hypomania ranged from 17.3% to 48.8% and was more frequent with antidepressant monotherapy compared to combination treatment with mood stabilizers. Depressive switches were detected in 5-16% of patients and were associated with antipsychotic use. Methodological heterogeneity and small sample sizes were limitations in the included studies.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Behavioral Sciences
Nicole M. Sekula, Anastasia K. Yocum, Steven Anderau, Melvin G. McInnis, David F. Marshall
Summary: This study reveals that comorbid migraine in patients with BD is associated with worse clinical outcomes, and the use of lithium may exacerbate manic symptoms in BD patients with a history of migraines.
BRAIN AND BEHAVIOR
(2022)
Article
Clinical Neurology
Camilla Gesi, Silvia Paletta, Maria Carlotta Palazzo, Bernardo Dell'Osso, Claudio Mencacci, Giancarlo Cerveri
Summary: Cariprazine is an antipsychotic medication approved for the treatment of schizophrenia, with a preference for dopamine D-3 receptors and also partial agonism at 5-HT1A receptors for an antidepressant effect. Common adverse events include extrapyramidal symptoms and akathisia. In addition to schizophrenia, cariprazine is also approved for the treatment of bipolar I disorder.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2021)
Article
Clinical Neurology
Jai Carmichael, Jennie Ponsford, Kate Rachel Gould, Gershon Spitz
Summary: The traditional approaches to measuring depression after traumatic brain injury (TBI) have limitations. This study adopted a symptom-oriented approach and found that post-TBI depression is highly heterogeneous. Different depressive symptoms have distinct associations with personal, injury-related, treatment, and outcome factors.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Letter
Clinical Neurology
Xiaoning Sun, Min Chen, Guanghai Wang, Fan Jiang
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Letter
Clinical Neurology
Aleksander Kwas
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Letter
Clinical Neurology
Josine E. Verhoeven, Laura K. M. Han, Brenda W. J. H. Penninx
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Review
Clinical Neurology
Erin Crowe, Petra K. Staiger, Steven J. Bowe, Imogen Rehm, Richard Moulding, Caitlyn Herrick, David J. Hallford
Summary: This study aimed to integrate the evidence regarding the relationship between emotion regulation difficulties and TTM symptoms, and found that individuals with higher levels of TTM severity appear to exhibit decreased overall emotion regulation abilities and strategies.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Letter
Clinical Neurology
Fjolla Berisha, Marjolaine Rivest-Beauregard, Jai Shah, Michelle Lonergan, Alain Brunet
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Article
Clinical Neurology
Yi-Tseng Tsai, Tzu-Jung Chuang, Sriyani Padmalatha Konara Mudiyanselage, Han-Chang Ku, Yi-Lin Wu, Chung-Yi Li, Nai-Ying Ko
Summary: Sleep disturbances are associated with higher suicide rates, and this association is independent of depression. Paying attention to sleep disturbances among PLHIV is crucial when monitoring suicidal ideation.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Article
Clinical Neurology
Junyou Chen, Ingrid D. Lui, Yu Cheng Hsu, Paul S. F. Yip
Summary: Despite rapid social changes in Hong Kong, marriage remains a strong protective factor against suicide for both men and women, particularly among younger individuals. Increasing suicide rates among divorced/separated, never-married, or widowed individuals suggest a need for more psychosocial support.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Article
Clinical Neurology
A. Perry, K. Gordon-Smith, K. J. S. Lewis, A. Di Florio, N. Craddock, L. Jones, I. Jones
Summary: This study found that the experience of losing at least one night of sleep was associated with an increased risk of postpartum psychosis in women with bipolar disorder. Sleep quality in late pregnancy was not associated with postpartum psychosis, and perinatal sleep disruption was not associated with postpartum depression.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Letter
Clinical Neurology
Dear J. Affect Disord, Mark J. Niciu, Robert C. Meisner, Brent R. Carr, Ali A. Farooqui, David Feifel, Adam Kaplin, Paul M. Kim, Christopher D. Schneck, Jennifer L. Vande Voort, Sagar Parikh, E. Jeremy Kendrick
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Article
Clinical Neurology
Tao Wang, Li Yang, Lan Yang, Bao-Peng Liu, Cun-Xian Jia
Summary: This study systematically reviewed the association between psychological pain and suicidality in patients with major depressive disorder (MDD). The results showed that psychological pain was a risk factor for suicidality in MDD patients, especially for those of advancing age. Reducing psychological pain in MDD patients is important for preventing suicidality.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Letter
Clinical Neurology
Juan Carlos Hugues, Abel Nogueira-Lopeza, Maeva Flayellea, Cora von Hammersteind, Joel Billieuxa
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Article
Clinical Neurology
Ogechi Cynthia Onyeka, Samuel D. Spencer, Alison Salloum, Katie Jiannetto, Eric A. Storch
Summary: This study examined the relationship among family accommodation (FA), posttraumatic stress symptoms (PTSS), and functional impairment. The results showed that FA was significantly associated with PTSS and functional impairment. Baseline FA partially mediated the relationship between baseline PTSS and functional impairment. Changes in FA from pre- to post-treatment were associated with relevant outcome variables at post-treatment and 12-month follow-up.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Article
Clinical Neurology
Yumeng Shi, Chao Yu
Summary: This study found a negative correlation between the intake of active microbes in the diet and depression.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Article
Clinical Neurology
Qiurui Nie, Yu Shen, Mengqin Luo, Zhiyong Sheng, Rui Zhou, Guangmin Li, Wei Huang, Shenjian Chen
Summary: The study assessed the sleep duration, sleep disorders, and trouble sleeping among adults in the United States from 2005 to 2018, revealing a high prevalence of abnormal sleep durations and increasing rates of sleep disorders and trouble sleeping.
JOURNAL OF AFFECTIVE DISORDERS
(2024)